In CRC profiles, resistance mutations that predict lack of benefit from EGFR antibodies alone or in combination with chemotherapies were frequently detected in KRAS (48.6%), BRAF (7.3%), or NRAS (4.3%) (Table 2). This evidence concerns the gene KRAS and colorectal carcinoma.